Tier 4 — mechanistic

Supplementary prevention and management of asthma with quercetin phytosome: a pilot registry

Maria R Cesarone, Gianni Belcaro, Shu Hu, Mark Dugall, Morio Hosoi, Andrea Ledda, Beatrice Feragalli, Claudia Maione, Roberto Cotellese
Minerva medica 2019 110(6):524-529

Bibliography

PubMed
PMID 31578841
DOI
10.23736/S0026-4806.19.06319-5
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPublished observational supplement registry with clinical outcomes
ModelHuman observational research
SampleAdults with mild-to-moderate asthma and rhinitis; sample size not stated in the abstract
InterventionOne or two quercetin-phytosome tablets/day plus standard management versus standard management
Duration30 days
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2019, this source examined allergies, histamine and mast cells. Design: Published observational supplement registry with clinical outcomes. Sample/model: Adults with mild-to-moderate asthma and rhinitis; sample size not stated in the abstract. The exposure or intervention was One or two quercetin-phytosome tablets/day plus standard management versus standard management. Follow-up or treatment period: 30 days.

The authors report favorable symptom, rescue-medication, and peak-flow findings in supplemented participants.

This is a published outcome study, not merely a trial registration. Nonrandomized supplementation, unclear masking, and formulation-specific exposure limit causal inference.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Allergies: Hay Fever Evidence and Limits. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The authors report favorable symptom, rescue-medication, and peak-flow findings in supplemented participants.
  • The recorded outcome domains were Symptoms and quality of life.
  • The exposure was observed rather than assigned as an isolated supplement treatment.

What this study can and cannot tell us

  • This is a published outcome study, not merely a trial registration. Nonrandomized supplementation, unclear masking, and formulation-specific exposure limit causal inference.
  • Confounding, dietary patterns, illness, medication use and reverse causation can influence an association. Blood or dietary concentrations do not identify the effect of starting a capsule.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology